Luly Jay R.'s Form 4 filing
Enanta Pharmaceuticals Inc (ENTA) · filed Dec 6, 2023
- Accession no.
- 0001062993-23-022045
- Filed
- Dec 6, 2023
- Trade date
- Dec 5, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $69.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Luly Jay R.CIK 0001571211 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2023 | Common Stock | SSaleDisposed | −7,230 | $9.63 | −$69,624.9 | 806,793 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.